AR055171A1 - Derivados de carboxamida como antagonistas del receptor muscarinico - Google Patents

Derivados de carboxamida como antagonistas del receptor muscarinico

Info

Publication number
AR055171A1
AR055171A1 ARP060104081A ARP060104081A AR055171A1 AR 055171 A1 AR055171 A1 AR 055171A1 AR P060104081 A ARP060104081 A AR P060104081A AR P060104081 A ARP060104081 A AR P060104081A AR 055171 A1 AR055171 A1 AR 055171A1
Authority
AR
Argentina
Prior art keywords
alkyl
optionally substituted
halo
independently selected
antagonists
Prior art date
Application number
ARP060104081A
Other languages
English (en)
Inventor
Paul Alan Glossop
John Simon Mantell
Ross Sinclair Strang
Christine Anne Louise Watson
Anthony Wood
Original Assignee
Pfizer Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Ltd filed Critical Pfizer Ltd
Publication of AR055171A1 publication Critical patent/AR055171A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/12—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

Reivindicacion 1: Un compuesto de formula (1) caracterizado porque R1 es CN o CONH2; A se selecciona entre los compuestos de formulas (2) a (4) en la que * y ** representan los puntos de union, estando ** unido al O, R2 y R3 son metilo o cuando A es un grupo de la formula (29 R2 y R3 también pueden formar junto con el átomo de C al que están unidos un anillo de ciclopentano; p es 0 o 1, A1 se selecciona entre a) fenilo opcionalmente sustituido con 1, 2 o 3 grupos seleccionados independientemente entre halo, CN, CF3, OR4, SR4, OCF3, alquilo C1-4 y fenilo opcionalmente sustituido con OH; b) naftilo opcionalmente sustituido con 1 o 2 grupos seleccionados entre halo, CN, CF3, OR4, SR4, OCF3 y alquilo C1-4; c) un grupo heterocíclico aromático bicíclico de 9 a 10 miembros, que contiene 1, 2 o 3 heteroátomos seleccionados independientemente entre O, S o N, estando dicho grupo heterocíclico opcionalmente sustituido con 1 o 2 sustituyentes seleccionados independientemente entre OR4, alquilo C1-4 y halo; R4 es H o alquilo C1-4; o, si es apropiado, las sales o solvatos farmacéuticamente aceptables del mismo.
ARP060104081A 2005-09-21 2006-09-18 Derivados de carboxamida como antagonistas del receptor muscarinico AR055171A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US71946705P 2005-09-21 2005-09-21
US71947705P 2005-09-21 2005-09-21
US71946805P 2005-09-21 2005-09-21

Publications (1)

Publication Number Publication Date
AR055171A1 true AR055171A1 (es) 2007-08-08

Family

ID=37698323

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060104081A AR055171A1 (es) 2005-09-21 2006-09-18 Derivados de carboxamida como antagonistas del receptor muscarinico

Country Status (43)

Country Link
US (3) US7772223B2 (es)
EP (1) EP1928821B1 (es)
JP (1) JP4221447B1 (es)
KR (1) KR100976909B1 (es)
CN (1) CN101268046B (es)
AP (1) AP1983A (es)
AR (1) AR055171A1 (es)
AT (1) ATE420069T1 (es)
AU (1) AU2006293618B9 (es)
BR (1) BRPI0616111B8 (es)
CA (1) CA2623332C (es)
CR (2) CR9814A (es)
CU (1) CU20100115A7 (es)
CY (1) CY1108880T1 (es)
DE (1) DE602006004768D1 (es)
DK (1) DK1928821T3 (es)
DO (1) DOP2006000202A (es)
EA (1) EA013083B1 (es)
EC (1) ECSP088265A (es)
ES (1) ES2318794T3 (es)
GE (1) GEP20104880B (es)
GT (1) GT200600422A (es)
HK (1) HK1117163A1 (es)
HN (1) HN2006032615A (es)
HR (1) HRP20090127T3 (es)
IL (1) IL189453A (es)
MA (1) MA29839B1 (es)
ME (1) ME01106B (es)
MX (1) MX2008002805A (es)
MY (1) MY143581A (es)
NL (1) NL2000241C2 (es)
NO (1) NO340975B1 (es)
NZ (1) NZ566023A (es)
PE (1) PE20070460A1 (es)
PL (1) PL1928821T3 (es)
PT (1) PT1928821E (es)
RS (2) RS50855B (es)
SI (1) SI1928821T1 (es)
TN (1) TNSN08137A1 (es)
TW (1) TWI322143B (es)
UY (1) UY29798A1 (es)
WO (1) WO2007034325A1 (es)
ZA (1) ZA200801432B (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008002246A1 (en) * 2006-06-28 2008-01-03 Astrazeneca Ab A pharmaceutical composition comprising an ikk2 inhibitor and a second active ingrdient.
DE602007005387D1 (de) * 2006-09-22 2010-04-29 Pfizer Ltd Ptors
DK2125714T3 (da) * 2007-03-16 2011-07-25 Pfizer Ltd Hydrochloridsalt af 5-[3-(3-hydroxyphenoxy)azetidin-1-yl]-5-methyl-2,2-diphenylhexanamid
JP5801997B2 (ja) 2009-07-07 2015-10-28 ファイザー・リミテッドＰｆｉｚｅｒ Ｌｉｍｉｔｅｄ 薬品の組合せを吸入するための投薬ユニット、投薬ユニットのパック、および吸入器
CN103201244B (zh) * 2010-08-26 2015-06-17 阿尔比马尔公司 用于制备1-溴代-2-(环丙基甲氧基)-5-氟代-4-甲氧基苯的方法
CN103242214B (zh) * 2013-05-02 2016-04-06 陕西步长高新制药有限公司 一种吲哚衍生物及其制备方法
KR101538846B1 (ko) 2013-07-30 2015-07-22 동아에스티 주식회사 신규한 바이페닐 유도체 및 그의 제조방법
EP3596046A1 (en) * 2017-03-15 2020-01-22 Mylan Laboratories Ltd. Novel polymorphs of (5-[3-(3-hydroxyphenoxy)azetidin-1-yl]-5-methyl-2,2-diphenylhexanamide hydrochloride
CN114732910A (zh) 2017-10-05 2022-07-12 弗尔康医疗公司 P38激酶抑制剂降低dux4和下游基因表达以用于治疗fshd
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
CN111423434A (zh) * 2019-01-09 2020-07-17 四川海思科制药有限公司 一种碳酰胺衍生物及其制备方法
WO2020261160A1 (en) * 2019-06-25 2020-12-30 Mylan Laboratories Limited Methods and intermediates for preparing hydrochloride salt of 5-[3-(3-hydroxyphenoxy)azetidin-1-yl]-5-methyl-2,2-diphenylhexanamide
EP4171525A1 (en) 2020-06-26 2023-05-03 Mylan Pharma UK Limited Formulations including 5-[3-(3-hydroxyphenoxy)azetidin-1-yl]-5-methyl-2,2-diphenylhexanamide
WO2023049696A1 (en) * 2021-09-21 2023-03-30 Corteva Agriscience Llc Methylation of 2-chloro-6-fluorophenol

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2886574A (en) * 1956-11-19 1959-05-12 Upjohn Co Quaternary ammonium salts of 2, 2-diphenyl-4, 4-dimethyl-4-pyrrolidino-butyramide
US4219559A (en) * 1979-01-10 1980-08-26 Janssen Pharmaceutica N.V. N-Heterocyclyl-4-piperidinamines
GB8824262D0 (en) * 1988-10-17 1988-11-23 Pfizer Ltd Therapeutic agents
US5070087A (en) * 1989-05-08 1991-12-03 A. H. Robins Company, Incorporated Aryl(alkyland alkylene)-N-((phenoxy and phenylthio)alkyl) aminoheterocyclics as cardiovascular, anthihistaminic, antisecretory and antiallergy agents
US5849761A (en) 1995-09-12 1998-12-15 Regents Of The University Of California Peripherally active anti-hyperalgesic opiates
HUP0001118A3 (en) * 1996-12-02 2001-06-28 Kyorin Seiyaku Kk N-substituted pyrrolidine derivatives, process for preparing the same and pharmaceutical compositions containing them
EP0848964B1 (de) * 1996-12-17 2007-07-25 Filtertek B.V. Rückschlagventil, insbesondere für die Medizintechnik
JPH11100366A (ja) * 1997-09-29 1999-04-13 Kyorin Pharmaceut Co Ltd 新規ｎ−置換環状アミン誘導体及びその製造法
US6673908B1 (en) * 1999-02-22 2004-01-06 Nuvelo, Inc. Tumor necrosis factor receptor 2
GB0011838D0 (en) 2000-05-17 2000-07-05 Astrazeneca Ab Chemical compounds
US6667344B2 (en) * 2001-04-17 2003-12-23 Dey, L.P. Bronchodilating compositions and methods
EA006505B1 (ru) 2001-12-20 2005-12-29 Лабораториос С.А.Л.В.А.Т.,С.А. Производные карбамата 1-алкил-1-азониабицикло[2.2.2]октана и их применение в качестве антагонистов мускаринового рецептора
MXPA03000145A (es) 2002-01-07 2003-07-15 Pfizer Compuestos de oxo u oxi-piridina como moduladores de receptores 5-ht4.
EP1375508A1 (en) 2002-06-27 2004-01-02 Aventis Pharma Deutschland GmbH N6-substituted adenosine analogues and their use as pharmaceutical agents
EP1554249A2 (en) 2002-09-17 2005-07-20 Actelion Pharmaceuticals Ltd. 1-pyridin-4-yl-urea derivatives

Also Published As

Publication number Publication date
NO20081001L (no) 2008-03-25
GEP20104880B (en) 2010-01-11
DOP2006000202A (es) 2007-04-15
JP2009508933A (ja) 2009-03-05
AU2006293618B9 (en) 2009-10-29
CA2623332C (en) 2012-05-01
ATE420069T1 (de) 2009-01-15
NL2000241C2 (nl) 2009-01-05
EP1928821B1 (en) 2009-01-07
US20110251164A1 (en) 2011-10-13
MA29839B1 (fr) 2008-10-03
EA200800540A1 (ru) 2008-08-29
WO2007034325A1 (en) 2007-03-29
HRP20090127T3 (en) 2009-06-30
MX2008002805A (es) 2008-04-07
ME01106B (me) 2013-03-20
TW200745024A (en) 2007-12-16
BRPI0616111B8 (pt) 2021-05-25
RS51680B (en) 2011-10-31
CN101268046A (zh) 2008-09-17
BRPI0616111A2 (pt) 2011-06-07
RS50855B (sr) 2010-08-31
DE602006004768D1 (de) 2009-02-26
MY143581A (en) 2011-05-31
NL2000241A1 (nl) 2007-03-22
PT1928821E (pt) 2009-03-10
PE20070460A1 (es) 2007-05-14
TNSN08137A1 (fr) 2009-07-14
BRPI0616111B1 (pt) 2019-10-08
US8268881B2 (en) 2012-09-18
ECSP088265A (es) 2008-04-28
KR100976909B1 (ko) 2010-08-18
US7772223B2 (en) 2010-08-10
AU2006293618B2 (en) 2009-10-08
ZA200801432B (en) 2009-07-29
HN2006032615A (es) 2010-10-04
NO340975B1 (no) 2017-07-31
CA2623332A1 (en) 2007-03-29
NZ566023A (en) 2010-02-26
EA013083B1 (ru) 2010-02-26
EP1928821A1 (en) 2008-06-11
TWI322143B (en) 2010-03-21
UY29798A1 (es) 2007-04-30
AU2006293618A1 (en) 2007-03-29
HK1117163A1 (en) 2009-01-09
RS20080119A (en) 2009-05-06
CR9814A (es) 2008-04-16
IL189453A (en) 2014-06-30
ES2318794T3 (es) 2009-05-01
KR20080037103A (ko) 2008-04-29
US20100029720A1 (en) 2010-02-04
CU23910B1 (es) 2013-06-29
US20070105831A1 (en) 2007-05-10
GT200600422A (es) 2007-05-28
US8486992B2 (en) 2013-07-16
CR20130209A (es) 2013-09-19
JP4221447B1 (ja) 2009-02-12
CN101268046B (zh) 2012-07-25
SI1928821T1 (sl) 2009-04-30
PL1928821T3 (pl) 2009-06-30
CU20100115A7 (es) 2011-10-14
IL189453A0 (en) 2008-08-07
CY1108880T1 (el) 2014-07-02
DK1928821T3 (da) 2009-03-16
AP1983A (en) 2009-03-24

Similar Documents

Publication Publication Date Title
AR055171A1 (es) Derivados de carboxamida como antagonistas del receptor muscarinico
CR9459A (es) Derivados benzodioxano y benzodioxolano y usos de los mismos
UY27322A1 (es) Nuevos derivados de indol con afinidad por el receptor 5-ht6
AR055878A1 (es) Derivados de ciclopropanocarboxamida
AR082562A1 (es) Derivados de isoxazolina como agentes antiparasitarios
CO5680412A2 (es) Agonistas del receptor adrenergico etilamino beta 2 sustituido con amino
ECSP034475A (es) Derivados de 4-fenil-piridin como antagonistas del receptor de neuroquinina-1
AR058546A1 (es) Derivados de 2- adamantilurea como inhibidores selectivos de 11 beta - hsd1
UY27336A1 (es) Derivados de 4-piperacinilindol con afinidad receptora de 5-ht6
PE20040832A1 (es) Derivados de indolil pirazinona
AR072952A1 (es) Compuestos de 2-imino-3-metilpirrolopirimidinona fenilo-sustituida como inhibidores de bace-1, composiciones y su uso
AR051461A1 (es) Compuesto de pirazolo[1,5-a]pirimidin-7-il-amina forma poliformica 1 de [3-(4-metoxi-2-metil-fenil)-2,5-dimetil-pirazolo[1,5-a]pirimidin-7-il]-[(s)-1-(3-metil-[1,2,4]oxadiazol-5-il)-propil]-amina, composicion farmaceutica que lo comprende y su uso para prepararla
AR035153A1 (es) Derivados de carboxamidas y cetonas de dihidrobenzodioxina
PE20080841A1 (es) Derivados de quinazolinona e isoquinolinona y su uso para el tratamiento o prevencion de trastornos relacionados con el estres o la depresion
CO5640117A2 (es) Derivados de 2,4-diamonopirimidina
CO5590957A2 (es) Amino-1,3,5-triazinas sustituidas en n con radicales biciclicos quirales, procedimiento para su preparacion, composiciones de las mismas y su uso como herbicidas y reguladores del crecimiento de las plantas
AR046297A1 (es) Inhibidores de la dpp - iv metodos para prepararlos y composiciones farmaceuticas que los contienen como agente activo
AR058124A1 (es) Derivados de ftalazinona como inhibidores de parp-1
EA200701640A1 (ru) Новые соединения с терапевтическим эффектом
AR009413A1 (es) Un compuesto, el cual es un derivado de distamicina benzoheterociclico, su utilizacion, un procedimiento para producirlo y una composicionfarmaceutica que lo comprende
AR053131A1 (es) Tetraciclinas 9-sustituidas
AR065863A1 (es) Derivados de imidazolidinona
AR047958A1 (es) Derivados de 1-bencil-5-piperazin-1-il-3,4 dihidro-1h-quinazolin-2-ona y sus derivados 1h-benzo(1,2,6)tiadiazina-2,2-dioxidos y 1,4-dihidro-benzo(d)(1,3)oxazinas-2-ona,como moduladores del receptor 5-ht,para el tratamiento de enfermedades del sistema nervioso central.
AR065583A1 (es) Compuestos macrociclicos y composicion farmaceutica
AR044662A1 (es) Compuestos de azetidina

Legal Events

Date Code Title Description
FG Grant, registration